Company profile

Ruizheng Gene company profile

AccurEdit develops and commercializes safe and targeted in vivo gene editing and delivery technologies to treat severe hereditary and acquired diseases globally. The company has built a leading end-to-end platform specializing in RNA synthesis, gene editing, and delivery for in vivo gene editing therapies.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
00051-00100 employees
Founded
2021-07-01

Headquarters

Headquarters
Fucheng, Shanxi, China
Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Total equity funding
$75M
Last funding
Series A / $75M / 2025-08-29
Last equity funding
Series A / $75M
Investors
4
Lead investors
3
Founders
2

Founders and investors

Founders

Jialin TaoYongzhen Wang

Lead investors

China Medical System Holdings LimitedLegend CapitalTibet Pharma

Investors

China Medical System Holdings LimitedCormorant Asset ManagementLegend CapitalTibet Pharma

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.